Real-time cognitive performance metrics derived from a digital therapeutic for inattention predict ADHD-related clinical outcomes: Replication across three independent trials of AKL-T01.

Caitlin A Stamatis^1,2, Andrew C Heusser³, Tony J Simon¹, Titiimaea Ala'ilima¹, Scott H Kollins^1,4

¹Akili Interactive Labs, Boston, MA, USA.

²Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

³Akili Interactive Labs, Boston, MA, USA. aheusser@akiliinteractive.com.

⁴Department of Psychiatry, Duke University School of Medicine, Durham, NC, USA.

PubMed PMC DOI PDF

Abstract

AKL-T01 is a digital therapeutic (DTx) that targets attention by generating conflict at dynamically updated difficulty levels during a multitasking game. Clinical trials support AKL-T01's efficacy in attention-deficit/hyperactivity disorder (ADHD), but there is a need to understand how in-game data can be used to monitor patient changes in cognition. We aimed to derive a real-time measure of atten…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.